Israeli medicine company aims to manufacture cannabinoid-producing cells

If successful, the cannabis industry would shift from agriculture-based growing into a full 3-D cell culturing platform for growing and expanding cannabinoid-producing cells.

May 8, 2019 15:54
1 minute read.
Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa

Biologists work in a laboratory at Pluristem Therapeutics Inc. in Haifa. (photo credit: BAZ RATNER/REUTERS)


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Pluristem Therapeutics, best known for developing novel placenta-based cell therapy products, announced May 6 that it has filed a US provisional patent application titled “Methods and Compositions for Producing Cannabinoids,” which covers the use of Pluristem’s state-of-the-art, proprietary 3-D cell culturing technology for the potential manufacturing of cannabinoid-producing cells.

If successful, this would shift the cannabis industry from agriculture-based growing into a full Good Manufacturing Practice (GMP) 3-D cell culturing platform for growing and expanding cannabinoid-producing cells. Today, manufacturing cannabinoid-producing cells is resource intensive for the number of cells it yields. Pluristem’s process, the company said, is expected to grow these cells in an automated and controlled manner at potentially significantly higher scales with the batch-to-batch consistency of commercial-grade products.

“We believe that Pluristem’s key competitive advantage is its advanced manufacturing platform that we developed in order to secure our leading position in the cell therapy industry with several product candidates in phase III studies,” said Pluristem president and co-CEO, Yaky Yanay. “Any future development with respect to cannabinoid-producing cells is expected to include third-party funding of development expenses. Further, in exploring such development, Pluristem intends to comply with applicable regulations and Nasdaq standards.”

He continued, “We look forward to further exploring the potential contribution our technology has on developing next-generation cannabinoid production while also potentially creating significant value for Pluristem’s shareholders.”

Until now, the Haifa-based company focused on the development of the world’s first placenta-based cell therapy products, which in studies have shown positive top-line results in the treatment of intermittent claudication (IC), an early stage of peripheral arterial disease.

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

May 23, 2019
Regenerative medicine firm CollPlant launches Israel R&D center